

Crossject benefits from The French National Recovery Plan, with a €1.5 million grant

Dijon, 19 FEBRUARY 2021

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing and soon marketing a portfolio of drug / device combinations for use in emergency situations, announces that it is a Recovery Plan beneficiary and has obtained €1.5 million in aid.

Patrick Alexandre, Chairman of the Management Board of Crossject, said: "It is a great source of pride for Crossject to have welcomed the French Finance Minister Bruno Le Maire today in our industrial unit in Arc-les-Gray. The Minister's interest in our medicines based on the ZENEO® needle-free auto-injector is the recognition of the work of all our teams. Being a stimulus plan beneficiary allows Crossject to receive €1.5 million in aid, which will help strengthen and secure our industrial facilities, and thus make the company even more credible with its existing and potential partners in Europe and the United States. This recognition inspires us even more in our ambition to save lives."

During his visit to the Crossject facility in Gray, Mister Bruno Le Maire, Minister of the Economy, Finance and Recovery, announced that Crossject was a beneficiary of the French Recovery plan. The plan is being implemented by the French government, with the support of the European Union, following the COVID-19 epidemic to support the most promising areas of productive industry in France. Within that framework, the Minister announced that Crossject is to receive €1.5 million in aid over the next 24 months.

This financial support, awarded by the stimulus plan operator Bpifrance in the form of a subsidy, will reinforce Crossject's cash position. As a reminder, Crossject raised € 12 million in funding on 14 December 2020.¹ At that time, Crossject was expecting to receive a further €3 million in 2021 (research tax credit, PIAVE, existing contracts, etc.), securing most of the company's cash requirements for the coming year. Since then, it has already received an advance of €1 million from Bpifrance under the PIAVE programme, in February. The €3 million anticipated will therefore be compounded by the additional €1.5 million in French Recovery Plan aid.

¹ See press release dated 14 December 2020



Contacts:

Crossject

Patrick Alexandre

info@crossject.com

Investor relations CIC

Market Solutions

Catherine Couanau +33 (0) 1 53 48 81 97

catherine.couanau@cic.fr

Press relations

Buzz & Compagnie

Mélanie Voisard +33 (0)3 80 43 54 89

melanie.voisard@buzzetcompagnie.com

Christelle Distinguin +33 (0)3 80 43 54 89

christelle.distinguin@buzzetcompagnie.com

About CROSSJECT • www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.